A long-acting flea and tick treatment from Merck Animal Health has earned approval for dogs at least six months old from the ...

Bravecto Quantum is the first FDA-approved drug that treats and prevents flea and tick infestations on dogs for a duration of ...

The U.S. Food and Drug Administration has approved Bravecto Quantum, a new shot that protects dogs six months or older ...

Rahway: Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., ...

The Food and Drug Administration has approved a first of its kind, once-yearly shot designed to protect dogs from fleas and ...

Fluralaner for extended-release injectable suspension (Bravecto Quantum) is also indicated for treatment of lone star tick in ...

Merck's animal health division received Food and Drug Administration approval for its once-yearly injectable flea-and-tick treatment for dogs. Merck Animal Health said Thursday it expects its Bravecto ...

Valued at a market cap of $204.3 billion, Merck & Co., Inc. (MRK) is a global healthcare company with a diverse portfolio ...

(Reuters) -Merck Animal Health, a unit of Merck, said on Thursday it would invest $895 million to expand its manufacturing facility in De Soto, Kansas.

AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, announced it has signed a binding evaluation and option agreement with Merck Animal Health to develop long-acting ...

DE SOTO, Kan. (KCTV) - Merck Animal Health is betting big on De Soto, announcing an $895 million expansion Thursday that marks one of the largest economic development projects in Kansas history.